Andrea S. Blevins Primeau, PhD, MBA

Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.

Most Recent Articles by Andrea S. Blevins Primeau, PhD, MBA

Nutraceuticals/Supplements and Cancer Prevention: All Hype?

Nutraceuticals/Supplements and Cancer Prevention: All Hype?

By

This fact sheet discusses the research on supplement use and cancer incidence.

Imatinib Determined the Most Cost-Effective Frontline TKI for Chronic Myeloid Leukemia

Imatinib Determined the Most Cost-Effective Frontline TKI for Chronic Myeloid Leukemia

By

Cost-effectiveness of TKIs for CML treatment is a complex topic that requires consideration of multiple factors — not just apparent costs to payers.

Familial Exposure to Radiation During Treatment for Cancer

Familial Exposure to Radiation During Treatment for Cancer

By

This fact sheet discusses the risk of familial exposure to radiation during cancer treatment and strategies to help limit incidental contact with potentially harmful byproducts.

Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC

Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC

By

Pembrolizumab monotherapy and pembrolizumab plus chemotherapy prolonged OS in recurrent/metastatic HNSCC.

First-Line Alectinib Effective in Asian Patients With <i>ALK</i>-Positive Advanced NSCLC

First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC

By

Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.

More Articles by Andrea S. Blevins Primeau, PhD, MBA

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs